Cabozantinib Development Program

Discovered by Exelixis, and the focus of our development and commercialization efforts, cabozantinib inhibits the activity of tyrosine kinases including MET, AXL, VEGF receptors, and RET and is recognized for its potential to treat a wide variety of cancers.

Filter by Therapeutic Area

Exelixis-Sponsored Trial

Investigator-Sponsored Trial

Collaboration with NCI’s 
Cancer Therapy Evaluation Program

Bristol-Myers Squibb Sponsored Trial

Sponsored by the European Organisation 
for Research and Treatment of Cancer (EORTC)

Phase 1
Phase 2
Phase 3
Genitourinary (GU) Cancers
COSMIC 021: Cabozantinib + Atezolizumab
(Advanced RCC, Advanced UC & CRPC)
Renal Cell Carcinoma Prostate Cancer Urothelial Carcinoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib + Docetaxel + Prednisone vs. Docetaxel + Prednisone
(Metastatic, Castrate-Resistant PC)
Prostate Cancer

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib + Nivolumab ± Ipilimumab
Any GU Tumors

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib + Pembrolizumab
(Metastatic UC Ineligible for Cisplatin)
Bladder Cancer Urothelial Carcinoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantib + Nivolumab
(Advanced or Metastatic Non-clear Cell RCC)
Renal Cell Carcinoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

PAPMET: Cabozantinib vs. Crizotinib vs. Sunitinib vs. Savolitinib
(Metastatic, Papillary RCC)
Renal Cell Carcinoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

CABOSUN II: Cabozantinib vs. Sunitinib
(Variant Histology RCC)
Renal Cell Carcinoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib
(Recurrent, Metastatic UC)
Bladder Cancer Urothelial Carcinoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

ATLANTIS: Cabozantinib vs. Placebo
(Metastatic Bladder Cancer; Maintenance Therapy after 1L Chemotherapy)
Bladder Cancer Urothelial Carcinoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib
(In Patients with Androgen Ablation)
Prostate Cancer

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

CheckMate 9ER: Cabozantinib + Nivolumab vs. Sunitinib
(First-line Advanced RCC)
Renal Cell Carcinoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Gastrointestinal (GI) Cancers
CAMILLA: Cabozantinib + Durvalumab
(Advanced CRC & HCC)
Colorectal Cancer Hepatocellular Carcinoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib ± Nivolumab
(Neoadjuvant, Locally Advanced HCC)
Hepatocellular Carcinoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

COSMIC 021: Cabozantinib + Atezolizumab
(Planned Expansion Cohorts in HCC & CRC)
Colorectal Cancer Hepatocellular Carcinoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

CaboMAb: Cabozantinib ± Panitumumab
(KRAS Wild-Type Metastatic CRC)
Colorectal Cancer

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib
(cMET Amplified Metastatic CRC)
Colorectal Cancer

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

CheckMate 040 Subgroup: Cabozantinib + Nivolumab ± Ipilimumab
(First-line and Previously Treated Advanced HCC)
Hepatocellular Carcinoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib
(Refractory, Metastatic CRC)
Colorectal Cancer

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

CABOGIST: Cabozantinib
(Metastatic GIST)
Gastrointestinal Stromal Tumor

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib + Erlotinib
(Metastatic Pancreatic Adenocarcinoma)
Pancreatic Cancer

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

CELESTIAL: Cabozantinib vs. Placebo
(Second- and Later-line Advanced HCC)
Hepatocellular Carcinoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Thyroid Cancer
COSMIC 021: Cabozantinib + Atezolizumab
(Planned Expansion Cohort in DTC)
Differentiated Thyroid Cancer

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib
(First-line, RAI-refractory DTC)
Differentiated Thyroid Cancer

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

COSMIC 311: Cabozantinib
(RAI-refractory DTC Previously Treated with VEGFR-targeted Therapy)
Differentiated Thyroid Cancer

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Lung Cancer
COSMIC 021: Cabozantinib + Atezolizumab
(Ongoing and Planned Expansion Cohorts in NSCLC)
Non-Small Cell Lung Cancer

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib
(With Brain Metastases with and without c-MET Amplification)
Non-Small Cell Lung Cancer

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib
(Molecular Alterations in RET, ROS1, MET, AXL, or NTRK1)
Non-Small Cell Lung Cancer

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Nivolumab vs. Cabozantinib + Nivolumab vs. Cabozantinib + Nivolumab + Ipilimumab
(NSCLC)
Non-Small Cell Lung Cancer

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Gynecologic Cancers
COSMIC 021: Cabozantinib + Atezolizumab
(Planned Expansion Cohorts in EC, Ovarian Cancer & Breast Cancer)
Breast Cancer Ovarian Cancer Endometrial Cancer

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Nivolumab ± Cabozantinib
(Advanced or Metastatic EC)
Endometrial Cancer

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib
(Recurrent, Clear Cell Carcinoma of the Ovary, Fallopian Tube, or Peritoneum)
Ovarian Cancer

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib ± Trastuzumab
(with Brain Metastases)
Breast Cancer

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib ± Fulvestrant
(Metastatic, Hormone-receptor-positive Breast Cancer with Involvement of Bone)
Breast Cancer

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib + Nivolumab
(Metastatic, Triple-negative Breast Cancer)
Breast Cancer

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Neuroendocrine Tumors (NET) & Carcinoid
Cabozantinib
(Advanced Pancreatic NET & Advanced Carcinoid)
NET & Carcinoid

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

CABINET: Cabozantinib vs. Placebo
(Advanced Neuroendocrine Tumors After Progression on Everolimus)
NET & Carcinoid

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Adrenocortical Carcinoma
Cabozantinib
(Metastatic Pheochromocytomas and Paragangliomas)
Adrenal Tumors

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib
(Metastatic Adrenocortical Carcinoma)
Adrenal Tumors

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Sarcoma
Cabozantinib vs. Placebo
(High-Grade Uterine Sarcoma)
Sarcoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib
(Metastatic Soft Tissue Sarcoma)
Sarcoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

CABONE: Cabozantinib
(Osteosarcomas and Ewing Sarcomas)
Sarcoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Neurofibroma
Cabozantinib in Plexiform Neurofibromas
Neurofibroma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Gastroesophogeal Cancer
CAMILLA: Cabozantinib + Durvalumab
(Advanced Gastric, Gastroesophageal or Esophageal Adenocarcinoma)
Gastroesophogeal Cancer Esophageal Cancer

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

COSMIC 021: Cabozantinib + Atezolizumab
(Planned Expansion Cohort in Gastric or Gastroesophageal Junction Adenocarcinoma)
Gastroesophogeal Cancer

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Head and Neck Cancer
Cabozantinib + Cetuximab
(Recurrent, Metastatic Squamous Cell Carcinoma)
Squamous Cell Carcinoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

COSMIC 021: Cabozantinib + Atezolizumab
(Planned Expansion Cohort in Head and Neck Cancer)
Head and Neck Cancer

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib + Pembrolizumab
(Recurrent, Metastatic Squamous Cell Carcinoma)
Squamous Cell Carcinoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Multiple Solid Tumor Types

Cabozantinib
(In Patients with HIV)
Multiple Solid Tumor Types


You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib
(In Patients with Bone Metastases, Non-Breast, Non-Prostate)
Multiple Solid Tumor Types


You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Multiple Myeloma
Cabozantinib + Carfilzomib
(Carfilzomib Refractory Multiple Myeloma)
Multiple Myeloma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Pediatric Cancer
Cabozantinib + Retinoic Acid
Pediatric Multiple Tumor Types

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib
(Children & Adolescents with Solid Tumors Including CNS Tumors)
Pediatric Multiple Tumor Types

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib in Plexiform Neurofibromas
Pediatric Neurofibroma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib
(High-Grade Pediatric Glioma)
Pediatric Glioma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

CABONE: Cabozantinib
(Osteosarcomas and Ewing Sarcomas; Patients 12+)
Pediatric Sarcoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib
(Refractory Sarcoma, Wilms Tumor, Other Rare Tumors)
Pediatric Multiple Tumor Types

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue